Benitec Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Benitec Biopharma Inc. on December 21, 2021, covering the event date of December 17, 2021. The filing reports the effective date of a corporate amendment approved by stockholders at the Annual Meeting held on December 8, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Authorized Share Increase: The Company's Amended and Restated Certificate of Incorporation was amended to increase the total number of authorized shares of common stock from 10,000,000 to 40,000,000.
- Effective Date: The Amendment was filed with the Secretary of State of Delaware and became effective on December 17, 2021.
- Security Holder Rights: This action constitutes a material modification to the rights of security holders, as noted in Item 3.03.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. The document serves solely to disclose the legal effectiveness of the share authorization increase.
Key Facts for Investor Verification
- Verify the new total authorized common share count is 40,000,000.
- Confirm the Amendment was filed with the Delaware Secretary of State on December 17, 2021.
- Review the definitive proxy statement on Schedule 14A (filed October 22, 2021) for the full material terms of the amendment.
- Note that this filing does not report any new financial data or operational results.